Good morning :)
$
₹
N

NeuroSense Therapeutics Ltd. Warrant

NRSNW

NASDAQ
N

NeuroSense Therapeutics Ltd. Warrant

NRSNW

NASDAQ
$0.0312.25% (-0.00)
$
₹
$0.0312.25% (-0.00)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
Loading...
1D
1W
1M
1Y
5Y
Max

Unknown

Sector and industry information not available

Unknown

Recent listing (market-cap unavailable as on date)

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

0
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-0.93
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

0%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Company Profile

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.

Peers

Peers

Hmm, looks like data is currently unavailable. Once it's updated, you can view it here

Financials

Financials

Income

Balance Sheet

Cash Flow

-2.3
-2.3
-3.2
-3.2
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Revenue
Net Income
Financial YearQ3 2023Q4 2023Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025
Total Revenue000000----
Net Income0.78-2.95-5.40-0.85-2.14-1.80-2.35-2.35-3.20-3.20
Net Profit Margin----------
See CostsAll values in $ Million

Frequently asked questions

  1. NeuroSense Therapeutics Ltd. Warrant (NRSNW) share price today is $0.03 as of September 23, 2026 at 1:30 AM IST. The stock touched a day high of $0.04 and a day low of $0.03.

  2. NeuroSense Therapeutics Ltd. Warrant stock trades on NASDAQ under the ticker symbol NRSNW.

  3. NeuroSense Therapeutics Ltd. Warrant's market capitalization is N/A as of September 23, 2026 at 1:30 AM IST.

  4. NeuroSense Therapeutics Ltd. Warrant's price-to-earnings (P/E) ratio is N/A as of September 22, 2026.

  5. NeuroSense Therapeutics Ltd. Warrant's price-to-book (P/B) ratio is 0 as of September 22, 2026.

  6. Yes, You can buy NeuroSense Therapeutics Ltd. Warrant shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy NeuroSense Therapeutics Ltd. Warrant shares in three steps: 1. Search NeuroSense Therapeutics Ltd. Warrant on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since NeuroSense Therapeutics Ltd. Warrant trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in NeuroSense Therapeutics Ltd. Warrant (NRSNW) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 284.9002 shares at the current price of $0.03.

Loading...